In a imiquimod-induced psoriasis mouse model, this MN system effectively alleviated skin lesion symptoms, reduced epidermal thickness, inflammatory cell infiltration, and inflammatory factors (e.g., TNF-α, IL-17), and suppressed the expression of angiogenesis-related proteins (CD31, VEGF). Here, IL17A is linked to psoriasis.